AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 1 - (NewsRx.com & NewsRx.net) -- Laboratory-based data confirm that phenoxodiol causes chemoresistant ovarian cancer cells to die. Researchers at Yale School of Medicine who conducted the study also found two signaling pathways that regulate ovarian cancer cells, indicating that phenoxodiol works by altering the signals made by these pathways.
The data were presented at the 50th annual scientific meeting of the Society for Gynecologic Investigation in Washington, DC.
Phenoxodiol is an experimental anticancer drug manufactured by Novogen, Ltd. and is being brought to market by its Marshall Edwards, Inc. (MEI) subsidiary. MEI was established to provide a commercial vehicle for Novogen's anticancer drug technology, the first of which is the novel anticancer drug phenoxodiol that Novogen has licensed to MEI. MEI is traded on London's AIM exchange.
"In the laboratory, we have identified phenoxodiol to be an extremely effective agent in causing ovarian cancer cells to undergo cell death," said researcher Thomas Rutherford, MD, assistant professor, department of obstetrics and gynecology at Yale School of Medicine. "Clinically, we are investigating possible toxicity and response at different dose levels in women with chemo-resistant ovarian ...
Source: HighBeam Research, Experimental anticancer agent phenoxodiol induces death of...